178 related articles for article (PubMed ID: 15963288)
1. Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001.
Pépin J; Mpia B
Emerg Infect Dis; 2005 Jun; 11(6):921-7. PubMed ID: 15963288
[TBL] [Abstract][Full Text] [Related]
2. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo.
Balasegaram M; Harris S; Checchi F; Ghorashian S; Hamel C; Karunakara U
Bull World Health Organ; 2006 Oct; 84(10):783-91. PubMed ID: 17128358
[TBL] [Abstract][Full Text] [Related]
3. High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo.
Robays J; Nyamowala G; Sese C; Betu Ku Mesu Kande V; Lutumba P; Van der Veken W; Boelaert M
Emerg Infect Dis; 2008 Jun; 14(6):966-7. PubMed ID: 18507916
[TBL] [Abstract][Full Text] [Related]
4. Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo.
Pyana Pati P; Van Reet N; Mumba Ngoyi D; Ngay Lukusa I; Karhemere Bin Shamamba S; Büscher P
PLoS Negl Trop Dis; 2014 Oct; 8(10):e3212. PubMed ID: 25275572
[TBL] [Abstract][Full Text] [Related]
5. Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.
Kazumba LM; Kaka JT; Ngoyi DM; Tshala-Katumbay D
PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006504. PubMed ID: 29897919
[TBL] [Abstract][Full Text] [Related]
6. Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy.
Pépin J; Milord F; Khonde A; Niyonsenga T; Loko L; Mpia B
Trans R Soc Trop Med Hyg; 1994; 88(4):447-52. PubMed ID: 7570842
[TBL] [Abstract][Full Text] [Related]
7. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.
Nok AJ
Parasitol Res; 2003 May; 90(1):71-9. PubMed ID: 12743807
[TBL] [Abstract][Full Text] [Related]
8. The phenomenon of treatment failures in Human African Trypanosomiasis.
Brun R; Schumacher R; Schmid C; Kunz C; Burri C
Trop Med Int Health; 2001 Nov; 6(11):906-14. PubMed ID: 11703845
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo.
Balasegaram M; Harris S; Checchi F; Hamel C; Karunakara U
Bull World Health Organ; 2006 Oct; 84(10):777-82. PubMed ID: 17128357
[TBL] [Abstract][Full Text] [Related]
10. Population genetics of Trypanosoma brucei gambiense in sleeping sickness patients with treatment failures in the focus of Mbuji-Mayi, Democratic Republic of the Congo.
Pyana PP; Sere M; Kaboré J; De Meeûs T; MacLeod A; Bucheton B; Van Reet N; Büscher P; Belem AMG; Jamonneau V
Infect Genet Evol; 2015 Mar; 30():128-133. PubMed ID: 25535944
[TBL] [Abstract][Full Text] [Related]
11. [A trial treatment with eflornithine of trypanosomiasis caused by Trypanosoma brucei gambiense in the Peoples Republic of the Congo].
Eozenou P; Jannin J; Ngampo S; Carme B; Tell GP; Schechter PJ
Med Trop (Mars); 1989; 49(2):149-54. PubMed ID: 2507863
[TBL] [Abstract][Full Text] [Related]
12. Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate.
Maina N; Maina KJ; Mäser P; Brun R
Acta Trop; 2007; 104(2-3):84-90. PubMed ID: 17765860
[TBL] [Abstract][Full Text] [Related]
13. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.
Bisser S; N'Siesi FX; Lejon V; Preux PM; Van Nieuwenhove S; Miaka Mia Bilenge C; Būscher P
J Infect Dis; 2007 Feb; 195(3):322-9. PubMed ID: 17205469
[TBL] [Abstract][Full Text] [Related]
14. [Melarsoprol].
Simon F
Med Trop (Mars); 1999; 59(4):331-2. PubMed ID: 10816741
[No Abstract] [Full Text] [Related]
15. Isolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory mice.
Pyana PP; Ngay Lukusa I; Mumba Ngoyi D; Van Reet N; Kaiser M; Karhemere Bin Shamamba S; Büscher P
PLoS Negl Trop Dis; 2011 Apr; 5(4):e1025. PubMed ID: 21526217
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda.
Legros D; Evans S; Maiso F; Enyaru JC; Mbulamberi D
Trans R Soc Trop Med Hyg; 1999; 93(4):439-42. PubMed ID: 10674099
[TBL] [Abstract][Full Text] [Related]
17. Gambian trypanosomiasis and synergism between melarsoprol and eflornithine: first case report.
Simarro PP; Asumu PN
Trans R Soc Trop Med Hyg; 1996; 90(3):315. PubMed ID: 8758090
[No Abstract] [Full Text] [Related]
18. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.
Matovu E; Enyaru JC; Legros D; Schmid C; Seebeck T; Kaminsky R
Trop Med Int Health; 2001 May; 6(5):407-11. PubMed ID: 11348535
[TBL] [Abstract][Full Text] [Related]
19. Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis.
Mpia B; Pépin J
Trop Med Int Health; 2002 Sep; 7(9):775-9. PubMed ID: 12225509
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis.
Pépin J; Mpia B
Trans R Soc Trop Med Hyg; 2006 May; 100(5):437-41. PubMed ID: 16483622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
